<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this study was to investigate the effects of tandospirone on <z:hpo ids='HP_0001251'>ataxia</z:hpo> in various types of <z:hpo ids='HP_0002503'>spinocerebellar degeneration</z:hpo> (SCD) </plain></SENT>
<SENT sid="1" pm="."><plain>Fifteen milligram per day of tandospirone was administered to 39 patients with SCD (<z:hpo ids='HP_0007263'>spinocerebellar atrophy</z:hpo> (SCA) 1, five patients; SCA2, six patients; <z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Machado-Joseph disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>), 14 patient; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA6</z:e>, five patients; multiple system <z:mpath ids='MPATH_127'>atrophy</z:mpath>-cerebellar type (MSA-C), seven patients; and multiple system <z:mpath ids='MPATH_127'>atrophy</z:mpath>-Parkinson type (MSA-P), two patients) </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were assessed before and 4 weeks after administration of the drug using the international cooperative <z:hpo ids='HP_0001251'>ataxia</z:hpo> rating scale total score (ARS), total length traveled (TLT) of body stabilometry, and a self-rating <z:hpo ids='HP_0000716'>depression</z:hpo> scale </plain></SENT>
<SENT sid="3" pm="."><plain>Statistically, ARS showed a significant difference in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> (p = 0.005) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA6</z:e> (p = 0.043) </plain></SENT>
<SENT sid="4" pm="."><plain>TLT also showed a significant difference in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> (p = 0.002) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA6</z:e> (p = 0.043) </plain></SENT>
<SENT sid="5" pm="."><plain>Eight of 39 patients (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA1</z:e>, 1/5; SCA2, 0/6; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>, 4/14; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA6</z:e>, 3/5; MSA-C, 0/7; and MSA-P, 0/2) showed more than a five point reduction in ARS, and 13 of 39 patients (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA1</z:e>, 0/5; SCA2, 1/6; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>, 8/14; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA6</z:e>, 4/5; MSA-C, 0/7; and MSA-P, 0/2) showed a reduction of TLT </plain></SENT>
<SENT sid="6" pm="."><plain>Our data indicate that the effects of tandospirone on <z:hpo ids='HP_0001251'>ataxia</z:hpo> are different between types of SCD </plain></SENT>
<SENT sid="7" pm="."><plain>Therefore, tandospirone is useful for <z:hpo ids='HP_0001251'>cerebellar ataxia</z:hpo> in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA6</z:e> </plain></SENT>
</text></document>